A continuous glucose
monitoring device that resides fully in the
subcutaneous tissue has the potential to greatly improve the management
of diabetes. Toward this goal, we have developed a competitive binding
glucose sensing assay based on fluorescently labeled PEGylated concanavalin-A
(PEGylated-TRITC-ConA) and mannotetraose (APTS-MT). In the present
work, we sought to contain this assay within the hollow central cavity
of a cylindrical hydrogel membrane, permitting eventual subcutaneous
implantation and optical probing through the skin. A “self-cleaning”
hydrogel was utilized because of its ability to cyclically deswell/reswell
in vivo, which is expected to reduce biofouling and therefore extend
the sensor lifetime. Thus, we prepared a hollow, cylindrical hydrogel
based on a thermoresponsive electrostatic double network design composed
of N-isopropylacrylamide and 2-acrylamido-2-methylpropanesulfonic
acid. Next, a layer-by-layer (LbL) coating was applied to the inner
wall of the central cavity of the cylindrical membrane. It consisted
of 5, 10, 15, 30, or 40 alternating bilayers of positively charged
poly(diallyldimethylammonium chloride) and negatively charged poly(sodium
4-styrenesulfonate). With 30 bilayers, the leaching of the smaller-sized
component of the assay (APTS-MT) from the membrane cavity was substantially
reduced. Moreover, this LbL coating maintained glucose diffusion across
the hydrogel membrane. In terms of sensor functionality, the assay
housed in the hydrogel membrane cavity tracked changes in glucose
concentration (0 to 600 mg/dL) with a mean absolute relative difference
of ∼11%.